UPB · CIK 0002022626
What Upstream Bio, Inc. told the SEC could break it.
Upstream Bio's flagged risks are entirely about U.S. trade and drug-pricing policy bearing on its lead candidate, verekitug. Some of its third-party manufacturers and API sources are outside the U.S., including in China, so tariff and trade-policy uncertainty could disrupt its supply — a threat sharpened by the administration's September 2025 announcement of a 100% tariff on brand-name or patented drugs unless companies expand U.S. manufacturing (currently on hold). And any future product would meet drug-pricing pressure: CMS's proposed most-favored-nation models (GLOBE for Part B, GUARD for Part D) would impose international-benchmark rebates on single-source drugs and sole-source biologics.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- MFN drug-pricing models (GLOBE / GUARD)medium
Proposed CMS most-favored-nation pricing models (GLOBE for Part B, GUARD for Part D) would mandate manufacturer rebates against international benchmark prices for single-source drugs and sole-source biologics.
“The first proposal, the Global Benchmark for Efficient Drug Pricing Model (“GLOBE”) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS's spending and eligibility criteria.”
- Offshore (incl. China) third-party manufacturing & API sourcing for verekitugmedium
Some third-party manufacturers are outside the US; trade-policy/tariff uncertainty with China could disrupt API imports and raw materials for verekitug.
“Some of our manufacturers are located outside of the United States. There is currently significant uncertainty about the future relationship between the United States and various other countries, including China, with respect to trade policies, treaties, government regulations and tariffs.”
- US 100% tariff on brand-name/patented drugsmedium
September 2025 administration announcement of a 100% tariff on brand-name/patented drugs absent US manufacturing expansion; currently on hold but a material supply-chain threat.
“Additionally, in September 2025, the current administration also announced a 100% tariff on brand-name or patented drugs unless pharmaceutical companies expand their manufacturing operations in the U.S., and may impose more restrictions on goods.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch